Tempus AI (NASDAQ:TEM) Trading 3.5% Higher – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares traded up 3.5% during trading on Friday . The stock traded as high as $49.40 and last traded at $49.72. 2,849,544 shares changed hands during trading, a decline of 43% from the average session volume of 5,025,887 shares. The stock had previously closed at $48.04.

Analysts Set New Price Targets

Several research analysts have commented on the company. Needham & Company LLC raised their price objective on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Bank of America raised their price objective on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Trading Up 4.6 %

The company has a 50 day moving average of $56.07 and a two-hundred day moving average of $51.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Buying and Selling

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the sale, the insider now owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the sale, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,598,969 shares of company stock worth $317,194,162 in the last ninety days.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Tempus AI by 13.2% in the 4th quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after buying an additional 278 shares during the period. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at about $30,000. Geode Capital Management LLC lifted its holdings in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the period. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at about $25,000. Finally, Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.